JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $75 to $78.
June 12, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Intra-Cellular Therapies and raises the price target from $75 to $78.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for ITCI.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100